发布求助
文献互助 智能选刊 最新文献

European Oncology and Haematology最新文献

筛选
英文 中文
Optimising Treatment in Relapsed, Refractory Multiple Myeloma 复发、难治性多发性骨髓瘤的优化治疗
European Oncology and Haematology Pub Date : 2018-01-01 DOI: 10.17925/EOH.2018.14.2.96
M. Minnema, M. Gavriatopoulou
{"title":"Optimising Treatment in Relapsed, Refractory Multiple Myeloma","authors":"M. Minnema, M. Gavriatopoulou","doi":"10.17925/EOH.2018.14.2.96","DOIUrl":"https://doi.org/10.17925/EOH.2018.14.2.96","url":null,"abstract":"Novel agents in multiple myeloma (MM), notably the proteasome inhibitors ixazomib and carfilzomib, the therapeutic monoclonal antibodies daratumumab and elotuzumab, and the new immunomodulatory drug pomalidomide, have helped to transform treatment paradigms for relapsed/refractory disease. Research into triplets containing novel agents has supported their superior efficacy over standard doublet combinations for relapsed/refractory MM. Toxicity profile is generally favourable and there is also emerging evidence of quality-of-life benefit. Importantly, novel agents can help address some of the key treatment challenges in myeloma, offering the opportunity for clinicians to more closely align therapeutic choices with individual patient needs. This is particularly important for specific subpopulations where obvious unmet needs still exist, such as in elderly, unfit or frail patients, those with high-risk cytogenetic abnormalities and patients burdened with toxicity-related complications and comorbidities. In this article, we review the available data and evidence for novel agents in the relapsed/refractory setting, and discuss their key role in tailored treatment strategies aimed at optimising current clinical practice.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"121 1","pages":"96"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74654001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Should we Address Biochemical Recurrence of Prostate Cancer as Soon as Possible? In Favour 前列腺癌生化复发是否应尽早解决?支持
European Oncology and Haematology Pub Date : 2018-01-01 DOI: 10.17925/EOH.2018.14.1.12
H. Poppel
{"title":"Should we Address Biochemical Recurrence of Prostate Cancer as Soon as Possible? In Favour","authors":"H. Poppel","doi":"10.17925/EOH.2018.14.1.12","DOIUrl":"https://doi.org/10.17925/EOH.2018.14.1.12","url":null,"abstract":"","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"42 1","pages":"12"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89109544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Should we Address Biochemical Recurrence of Prostate Cancer as Soon as Possible? Against 前列腺癌生化复发是否应尽早解决?反对
European Oncology and Haematology Pub Date : 2018-01-01 DOI: 10.17925/EOH.2018.14.1.14
R. Chandler, A. Petremolo, P. Rescigno, J. Bono
{"title":"Should we Address Biochemical Recurrence of Prostate Cancer as Soon as Possible? Against","authors":"R. Chandler, A. Petremolo, P. Rescigno, J. Bono","doi":"10.17925/EOH.2018.14.1.14","DOIUrl":"https://doi.org/10.17925/EOH.2018.14.1.14","url":null,"abstract":"","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"3 1","pages":"14"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74242560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiopharmaceuticals for the Detection of Recurrent Prostate Cancer 检测复发性前列腺癌的放射性药物
European Oncology and Haematology Pub Date : 2018-01-01 DOI: 10.17925/EOH.2018.14.1.16
B. Tombal
{"title":"Radiopharmaceuticals for the Detection of Recurrent Prostate Cancer","authors":"B. Tombal","doi":"10.17925/EOH.2018.14.1.16","DOIUrl":"https://doi.org/10.17925/EOH.2018.14.1.16","url":null,"abstract":"","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"4 1","pages":"16"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87968547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
More than a Gel & Hyaluronic Acid, a Central Component in the Microenvironment of Pancreatic Cancer 不仅仅是凝胶和透明质酸，胰腺癌微环境中的核心成分
European Oncology and Haematology Pub Date : 2018-01-01 DOI: 10.17925/EOH.2018.14.1.40
T. Seufferlein, M. Ducreux, M. Hidalgo, G. Prager, E. Cutsem
{"title":"More than a Gel & Hyaluronic Acid, a Central Component in the Microenvironment of Pancreatic Cancer","authors":"T. Seufferlein, M. Ducreux, M. Hidalgo, G. Prager, E. Cutsem","doi":"10.17925/EOH.2018.14.1.40","DOIUrl":"https://doi.org/10.17925/EOH.2018.14.1.40","url":null,"abstract":"1. Klinik für Innere Medizin I, Universitätsklinikum Ulm, Ulm, Germany; 2. Département de Médecine Oncologique, Institut Gustave Roussy, Villejuif, France and Université Paris-Saclay, Paris, France; 3. Harvard Medical School, Boston, Massachusetts, United States; 4. Department of Medicine I, Comprehensive Cancer Centre Vienna, Medical University Vienna, Vienna, Austria; 5. Gastroenterology/Digestive Oncology, University Hospitals Leuven and KU Leuven, Leuven, Belgium","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"84 1","pages":"40"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89026075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Whole-body Vibration Training as a Supportive Therapy During Allogeneic Haematopoietic Stem Cell Transplantation – A Randomised Controlled Trial 全身振动训练作为异体造血干细胞移植的支持疗法-一项随机对照试验
European Oncology and Haematology Pub Date : 2018-01-01 DOI: 10.17925/EOH.2018.14.1.33
T. S. Kaeding, M. Frimmel, Florian Treondlin, K. Jung, W. Jung, G. Wulf, L. Trümper, J. Hasenkamp
{"title":"Whole-body Vibration Training as a Supportive Therapy During Allogeneic Haematopoietic Stem Cell Transplantation – A Randomised Controlled Trial","authors":"T. S. Kaeding, M. Frimmel, Florian Treondlin, K. Jung, W. Jung, G. Wulf, L. Trümper, J. Hasenkamp","doi":"10.17925/EOH.2018.14.1.33","DOIUrl":"https://doi.org/10.17925/EOH.2018.14.1.33","url":null,"abstract":"1. Institute of Sport Science & University Medical Center Göttingen, Faculty of Rehabilitation and Sports Medicine, Göttingen, Germany; 2. Institute of Sports Medicine, Hannover Medical School (MHH), Hannover, Germany; 3. Clinic for Hematology and Medical Oncology with Department of Stem Cell Transplantation, Göttingen Comprehensive Cancer Center, University Medical Center Göttingen, Göttingen, Germany; 4. Medical Biometry and Statistical Bioinformatics, University Medical Center Göttingen, Göttingen, Germany","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"156 1","pages":"33"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84944726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Treatment Resistant denovoEpidermal Growth Factor Receptor (EGFR)-mutated Small Cell Lung Cancer 治疗耐药表皮生长因子受体(EGFR)突变的小细胞肺癌
European Oncology and Haematology Pub Date : 2018-01-01 DOI: 10.17925/EOH.2018.14.2.84
B. Petricevic, R. Tay, R. Califano, Wilhelminenspital Vienna Austria Hematology
{"title":"Treatment Resistant denovoEpidermal Growth Factor Receptor (EGFR)-mutated Small Cell Lung Cancer","authors":"B. Petricevic, R. Tay, R. Califano, Wilhelminenspital Vienna Austria Hematology","doi":"10.17925/EOH.2018.14.2.84","DOIUrl":"https://doi.org/10.17925/EOH.2018.14.2.84","url":null,"abstract":"","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"19 1","pages":"84"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74375266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Novel Options in Metastatic and Non-surgically Curable Bladder Cancer 转移性和非手术可治愈膀胱癌的新选择
European Oncology and Haematology Pub Date : 2018-01-01 DOI: 10.17925/EOH.2018.14.2.87
Elise Vong, J. Samol
{"title":"Novel Options in Metastatic and Non-surgically Curable Bladder Cancer","authors":"Elise Vong, J. Samol","doi":"10.17925/EOH.2018.14.2.87","DOIUrl":"https://doi.org/10.17925/EOH.2018.14.2.87","url":null,"abstract":"For over two decades, the prognosis of patients with metastatic or locally advanced non-resectable bladder cancer has remained poor, with no significant advances in life-prolonging treatment, especially following progression on platinum-based chemotherapy or for cisplatin-ineligible patients. In recent years, immunotherapy has changed the standard of care for an increasing number of tumour types, including bladder cancer. Here, we will review the current evidence of the clinical usage of immune checkpoint inhibitors with a focus on programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors, as well as their toxicities, potential biomarkers and predictors of response, and provide an outline of future directions in the treatment of patients with metastatic and/or non-surgically curable urothelial bladder cancer.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"47 1","pages":"87"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76495844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting the FLT3 Mutation in Acute Myeloid Leukaemia 靶向FLT3突变的急性髓性白血病
European Oncology and Haematology Pub Date : 2017-01-01 DOI: 10.17925/EOH.2017.13.02.139
S. Kayser, R. Schlenk
{"title":"Targeting the FLT3 Mutation in Acute Myeloid Leukaemia","authors":"S. Kayser, R. Schlenk","doi":"10.17925/EOH.2017.13.02.139","DOIUrl":"https://doi.org/10.17925/EOH.2017.13.02.139","url":null,"abstract":"","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"11 1","pages":"139"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88711314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Can we Continue to Afford Access to Cancer Treatment 我们能继续负担得起癌症治疗吗
European Oncology and Haematology Pub Date : 2017-01-01 DOI: 10.17925/EOH.2017.13.02.114
N. Wilking, G. Lopes, K. Meier, S. Simoens, W. Harten, A. Vulto
{"title":"Can we Continue to Afford Access to Cancer Treatment","authors":"N. Wilking, G. Lopes, K. Meier, S. Simoens, W. Harten, A. Vulto","doi":"10.17925/EOH.2017.13.02.114","DOIUrl":"https://doi.org/10.17925/EOH.2017.13.02.114","url":null,"abstract":"O ncology is facing a crisis of affordability that is not sustainable. The economic burden of cancer is growing, as a result of the rising cancer incidence and increased survival, alongside growing investment in disease prevention, diagnosis and treatment. The prices of new cancer drugs continue to increase, placing growing pressure on many healthcare systems. The aim of this article is to explore the reasons why the cost of cancer care is increasing, and why this increase may become unsustainable unless changes are made. There are only limited options for future health spending. Finding ways to improve the allocation of existing resources to achieve the best outcomes for patients will be key to achieving sustainability, whilst safeguarding the continued development of new, effective cancer treatments. Currently, too many cancer drugs are approved without robust evidence of value, and spending more on treatments does not necessarily translate to improvements in health. For all new drugs, in addition to efficacy and safety, there should be a focus on value, with measured outcomes and pricing that ensures these drugs are affordable. Fundamental changes to healthcare systems and industry are needed to sustain cancer care and allow continued access to effective and safe treatments for all patients.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"14 1","pages":"114"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78568670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 21
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信